{"analyses":[{"ciLowerLimit":"1.619","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.722","groupDescription":"Stratified analysis: Stratified by disease site (visceral, non-visceral) per randomization.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.0001","pValueComment":"1-sided p-value is from exact test.","paramType":"Odds Ratio (OR)","paramValue":"2.451","statisticalMethod":"Fisher Exact"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"82.2","upperLimit":"88.9","value":"85.8"},{"groupId":"OG001","lowerLimit":"64.7","upperLimit":"77.0","value":"71.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"444"},{"groupId":"OG001","value":"222"}],"units":"Participants"}],"description":"DC is defined as overall CR, PR, or stable disease (SD) \\>=24 weeks according to RECIST version 1.1. Disease Control Rate (DCR) is defined as participants with CR, PR, or SD \\>=24 weeks relative to all randomized participants. Participants who do not have on-study radiographic tumor reevaluation, who received anti-tumor treatment, a best response of SD\\>=24 weeks, or who died, progressed, or dropped out for any reason prior to achieving reaching a CR or PR and a best response of SD\\>=24 weeks was counted as non-responders in DCR. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \\<10mm). PR: \\>=30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. SD: neither sufficient shrinkage nor increase to qualify for disease progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received letrozole 2.5 milligram (mg) orally QD (once daily) combined with palbociclib 125 mg QD for 21 days of every-28-day cycle, followed by 7 days off treatment.","id":"OG000","title":"Palbociclib Plus Letrozole"},{"description":"Participants received letrozole 2.5 mg orally QD combined with placebo QD for 21 days of every-28-day cycle, followed by 7 days off treatment.","id":"OG001","title":"Placebo Plus Letrozole"}],"paramType":"NUMBER","populationDescription":"ITT population or full analysis set included all participants who were randomized, with study medication, regardless of whether participants received study medication or received a different drug from that to which they were randomized.","reportingStatus":"POSTED","timeFrame":"From randomization until end of treatment (up to approximately 2.5 years)","title":"Disease Control (DC)/Clinical Benefit Response (CBR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}